TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03314584

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
Study: NCT03901430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group navigation model
Description: In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
Study: NCT03330899

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant SE
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant SE
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen + adjuvant SE
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 antigen without adjuvant
Description: H7N9 monovalent (fragmented and inactivated)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBS)
Description: Placebo (Phosphate Buffered Saline -PBS)
Study: NCT03783650

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QIC with PCP and without subspecialist
Description: During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QIC with PCP and without subspecialist
Description: During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QIC with Subspecialist
Description: Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QIC with Subspecialist
Description: Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
Study: NCT02245698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT01494103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iCaspase9-transduced T cells
Description: Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
Study: NCT03783650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hub and Spoke co-management
Description: Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hub and Spoke co-management
Description: Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainability of changes
Description: Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
Study: NCT00819208

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise intervention
Description: 3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Description: Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Once at the beginning of the program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Every 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Every 12 months
Study: NCT01494103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse.
Study: NCT00819208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables
Description: Every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables
Description: Every 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fatigue assessment and management
Description: Every 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fatigue assessment and management
Description: Every 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Every 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: For Arm 2 just once at beginning of program.
Study: NCT00819208

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitness testing
Description: Objective fitness testing for both arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitness testing
Description: Objective fitness testing for both arms
Study: NCT03871517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
Study: NCT00631488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893
Description: Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893
Description: Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for MK-0893
Description: Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sitagliptin
Description: Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Metformin
Description: Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
Study: NCT02018952

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonography assessment
Description: All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome
Study: NCT02322320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
Study: NCT01476176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol
Description: experimental paracetamol with caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol marketed formulation
Description: marketed formulation containing caffeine
Study: NCT01280890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training using VIPS
Description: Staff training using the VIPS framework

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training using DCM
Description: The staff will be supervised using Dementia Care Mapping

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Filmed traditional Lectures will be given to care staff
Study: NCT01766830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rk28 ICT
Description: rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IT LEISH (rK39)
Description: IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunochromatographic HAT test
Description: This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
Study: NCT03685188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Citrate
Description: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
Study: NCT02833350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Study: NCT01327469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole, 2 x 400mg
Description: Albendazole 2 x 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole 400mg
Description: Albendazole 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole 500mg
Description: Mebendazole 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole 2 x 500mg
Description: Mebendazole 2 x 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrantel-oxantel + mebendazole
Description: Pyrantel-oxantel + mebendazole
Study: NCT01311648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973)
Description: Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973)
Description: Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
Study: NCT01579656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salba
Description: 25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poppy
Description: 25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: 25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sesame
Description: 25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
Study: NCT04330443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Description: To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
Study: NCT00699738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Breastfeeding

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bottlefeeding
Description: Bottlefeeding
Study: NCT03764345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)
Description: Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
Study: NCT04587479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-8263
Description: Variable dose, orally Q2D with 28 days each cycle
Study: NCT01171924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-101
Description: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-101
Description: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
Study: NCT00388011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Morphine (MNS075) 3.75 mg
Description: Intranasal Morphine (MNS075) 3.75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine 7.5 mg
Description: Intravenous Morphine 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine (MNS075) 7.5 mg
Description: Intranasal morphine (MNS075) 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine (MNS075) 15 mg
Description: Intranasal morphine (MNS075) 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal morphine (MNS075) 30 mg
Description: Intranasal morphine (MNS075) 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Intranasal placebo